# Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

> **NCT04954989** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Megalabs** · enrollment: 52 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU
- **BIOLOGICAL:** Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU

## Key facts

- **NCT ID:** NCT04954989
- **Lead sponsor:** Megalabs
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-06
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954989, "Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04954989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*